MTMitsuru Toda

Mitsuru Toda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mitsuru Toda has a total of 262 co-authors. Here are the top co-authors by number of shared publications:

  • Kaitlin Benedict

    Mycotic Diseases Branch, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia

    17 shared publications
  • Samantha L. Williams

    Mycotic Diseases Branch, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia

    8 shared publications
  • Brendan R. Jackson

    Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA

    7 shared publications
  • Dallas J. Smith

    Mycotic Diseases Branch, Centers for Disease Control and Prevention

    6 shared publications
  • Tom Chiller

    Mycotic Diseases Branch, Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia

    6 shared publications
  • Ian Hennessee

    Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia

    5 shared publications

Latest Publications

  • Top Cited Papers

    Candida glabrata emerges as the most common cause of candidemia: analysis of a large hospital-based database, United States, 2016–2024

    by Jeremy A W Gold, Kaitlin Benedict, Meghan Lyman, Mitsuru Toda, Jessica S Little, Luis Ostrosky-Zeichner

    Using a large U.S. hospital database, we described 13,177 candidemia-associated hospitalizations during 2016–2024. In 2024, Candida glabrata surpassed C. albicans, and C. auris, previously rare, ranked fifth. These findings underscore the importance of ongoing surveillance and adherence to guidelines for candidemia treatment and testing.


  • Open Access

    Blastomyces Urine Antigen Testing for Active Case Identification During a Blastomycosis Outbreak

    by Allyson W. O’COnnor, Ian Hennessee, Perri C. Callaway, Marcia L. Stanton, Xiaoming Liang, Ju-Hyeong Park, Ryan LeBouf, Rachel L. Bailey, Rebecca Reik, Mary Grace Stobierski, et al.

    Urine antigen testing for blastomycosis outbreaks


  • Coccidioidomycosis-Associated Hospitalizations, United States, 2016–2021

    by Samantha L Williams, Kaitlin Benedict, Ian Hennessee, Mitsuru Toda

    Using a large hospital discharge database, we summarize 54 985 coccidioidomycosis-associated hospitalizations during 2016–2021 in the United States. Hospitalization rates per 100 000 population increased from 2.3 in 2016 to 3.2 in 2021. Our findings underscore the importance of clinical awareness and vigilance for coccidioidomycosis to achieve better patient outcomes.


  • Impact of Delays in Diagnosis on Healthcare Costs Associated With Blastomycosis, Coccidioidomycosis, and Histoplasmosis in a Commercially Insured Population

    by Kaitlin Benedict, Jason Massey, Michelle Fearon Scales, Ian Hennessee, Samantha L Williams, Mitsuru Toda

    Among patients with blastomycosis (n = 281), coccidioidomycosis (n = 1920), and histoplasmosis (n = 2180), 62% experienced diagnostic delays (mean 29 days). Patients who experienced delays incurred average excess healthcare costs of up to $15 648 (95% confidence interval: $8600–$22 695) compared with those without a delay. Earlier diagnosis may help reduce excess costs.


  • Comparison of Patients With Coccidioidomycosis in Arizona Versus California: A Commercial Health Insurance Claims Analysis

    by Kaitlin Benedict, Ian Hennessee, Gail Sondermeyer Cooksey, Fariba M Donovan, George R Thompson, Thomas Williamson, Mitsuru Toda

    Commercially insured patients with coccidioidomycosis in Arizona (n = 1640) were more likely to have symptoms indicating acute pulmonary disease (eg, cough, dyspnea, chest pain) compared with patients in California (n = 701), who were more likely to have disseminated coccidioidomycosis, possibly reflecting differences in exposure, healthcare seeking, or clinical management.


  • Using Machine Learning Algorithms to Identify Key Predictors of Invasive Mold Infection Surveillance

    by Samantha L Williams, Zainab Salah, Brendan R Jackson, Sebastian Wurster, Jose A Serpa, Carolyn Z Grimes, Robert L Atmar, Tom M Chiller, Dimitrios P Kontoyiannis, Luis Ostrosky-Zeichner, et al.

    Background: Invasive mold infections (IMI) can lead to severe morbidity and mortality, but routine public health surveillance is lacking. Although extensive evaluation is needed for clinical diagnosis, case classification prediction models may inform surveillance efforts, which are essential to better characterize epidemiologic trends and assess the value of a more inclusive IMI case definition. Methods: We modeled medical record data of potential IMI cases from 4 medical centers in Houston, Texas, during September 2016 to August 2018. We used least absolute shrinkage and selection operator and random forest machine learning methods to identify key host and clinical factors, mycological evidence, diagnostics, and health care exposures predictive of IMI case versus noncase status using both conventional and novel definitions. We assessed feature importance by measuring each variable's impact on prediction error using leave-one-covariate-out and permutation feature importance approaches. Results: Receipt of systemic antifungal medication, hospital billing codes related to IMI, and positive pulmonary histopathology results were identified as the most important predictors of IMI case status across all measures. Removal of these features from the models resulted in reductions to prediction accuracy ranging from 3.6% (95% confidence interval [CI], 3.2%–3.2%) to 7.6% (95% CI, 7.2%–8.0%). Some IMI risk factors, including cancer diagnosis and prolonged receipt of corticosteroid medications, worsened prediction in several assessments of feature importance. Conclusions: Features identified as important predictors of IMI case status using machine learning methods deviated from classic IMI risk factors. Our results will inform robust and feasible IMI case prediction models for public health surveillance.

  • Top Cited Papers
    Open Access

    Estimated Burden of Coccidioidomycosis

    by Samantha L. Williams, Kaitlin Benedict, Brendan R. Jackson, Malavika Rajeev, Gail Cooksey, Irene Ruberto, Thomas Williamson, Rebecca H. Sunenshine, BreAnne Osborn, Hanna N. Oltean, et al.

    Importance: Coccidioidomycosis is an underrecognized fungal infection that can cause serious illness and constitutes a considerable public health burden. The number of cases is likely substantially higher than the nationally reported total, as surveillance does not capture patients who do not seek medical care or who are undiagnosed or misdiagnosed. Coccidioidomycosis is not reportable in all states, and cases not reported to public health entities are likewise missed. A systematic estimate of coccidioidomycosis burden is needed to raise awareness and inform public health interventions and policy.Objective: To assess the annual burden of symptomatic coccidioidomycosis in the US.Design, Setting, and Participants: This cross-sectional study developed models incorporating coccidioidomycosis cases reported to the National Notifiable Diseases Surveillance System from January 1 to December 31, 2019, as model inputs. Multipliers from US public health surveillance accounted for factors including health care–seeking behavior, underdiagnosis, underreporting, and in-hospital mortality. Multiplier values were sourced from a combination of literature review and expert opinion. Regional estimates were generated using endemicity levels categorized as high (Arizona and California), low (Nevada, New Mexico, Texas, Utah, and Washington), or unknown (all other states and Washington, DC). Data were accrued from January 1, 2022, to July 1, 2024, and analyzed from October 1, 2022, to September 1, 2024.Exposure: Coccidioidomycosis reported to public health surveillance entities.Main Outcomes and Measures: Models estimated annual incident symptomatic coccidioidomycosis cases, hospitalizations, and deaths nationally and regionally in the US.Results: A nationwide total of 273 000 (95% credible interval [CrI], 206 000-360 000) incident symptomatic coccidioidomycosis cases were estimated in 2019. High-endemic states accounted for the highest burden (125 000 [95% CrI, 94 000-165 000] cases), followed by states of unknown endemicity (103 000 [95% CrI, 66 000-155 000] cases) and low-endemic states (46 000 [95% CrI, 31 000-65 000] cases). Nationally, models estimated 23 000 annual hospitalizations (95% CrI, 18 000-28 000) and 900 annual deaths (95% CrI, 700-1100) associated with coccidioidomycosis.Conclusions and Relevance: In this cross-sectional study, the estimated national burden of symptomatic coccidioidomycosis in 2019 was 10 to 18 times higher than the number of cases reported through national surveillance. Better awareness, diagnostic testing practices, and reporting are needed to improve patient outcomes and enhance our understanding of coccidioidomycosis epidemiology.


  • Impact of Fluconazole on Outcomes of Patients With Primary Pulmonary Coccidioidomycosis: A Commercial Health Insurance Claims-based, Propensity Score Matched Analysis

    by Kaitlin Benedict, Ian Hennessee, Dallas J Smith, Mitsuru Toda, George R Thompson

    Background: Patients with pulmonary coccidioidomycosis often experience prolonged symptoms lasting from weeks to months. Limited data exist regarding whether fluconazole prevents development of disseminated disease or shortens symptom duration. We describe factors associated with fluconazole receipt and assess its effect on outcomes among patients with pulmonary coccidioidomycosis. Methods: Using the MerativeTM MarketScan® Commercial Database, we identified immunocompetent patients ages 18–64 with incident pulmonary coccidioidomycosis during 2017–2023 and continuous enrollment in the 180 days before and after diagnosis. We examined demographic and clinical differences between patients treated versus not treated with fluconazole and performed 1:1 greedy nearest neighbor propensity score matching to control for these differences. We performed bivariate analyses on the matched subset to evaluate patient outcomes by fluconazole receipt. Results: Among 1448 patients with pulmonary coccidioidomycosis, 659 (46%) received fluconazole. Patients who received fluconazole more frequently had pre-diagnosis symptoms (95% vs 72%, P < .001) and antibiotic prescriptions (68% vs 32%, P < .001) than those who did not. Among the propensity score matched subset (n = 696), hospitalization (4% vs 1%, P = .004) and disseminated coccidioidomycosis (3% vs 0%, P = .006) were more frequent among patients who received fluconazole. The median number of days from diagnosis to last visit for chest pain (50.0 vs 46.5), cough (64.0 vs 39.0), fatigue (63.0 vs 65.5), myalgia (98.0 vs 74.0), and joint pain (93.5 vs 107.5) was not significantly different between treatment groups. Conclusions: Our results support existing guidelines that fluconazole may not be associated with improved outcomes for certain immunocompetent patients with pulmonary coccidioidomycosis.


  • Open Access

    Epidemiological and Clinical Features of a Large Blastomycosis Outbreak at a Paper Mill in Michigan

    by Ian Hennessee, Sara Palmer, Rebecca Reik, Arianna Miles-Jay, Muhammad Yasir Nawaz, Heather M Blankenship, Rebecca Kramer, Adam Hughes, Michael Snyder, Robert L Yin, et al.

    Blastomycosis is an environmentally acquired fungal infection that can result in severe pulmonary illness and high hospitalization rates. In 2023, a blastomycosis outbreak was detected among workers at a paper mill in Delta County, Michigan. We included patients with clinical and laboratory evidence of blastomycosis who had spent ≥40 hours in Delta County since September 1, 2022 and had illness onset December 1, 2022–July 1, 2023. We assessed epidemiological and clinical features of patients and evaluated factors associated with hospitalization. We performed whole-genome sequencing to characterize genetic relatedness of clinical isolates from eight patients. In total, 131 patients were identified; all had worked at or visited the mill. Sixteen patients (12%) were hospitalized; one died. Compared with non-hospitalized patients, more hospitalized patients had diabetes (p=0.03) and urine antigen titers above the lower limit of quantification (pBlastomyces gilchristii and clustered into a distinct outbreak cluster. This was the largest documented blastomycosis outbreak in the United States. Epidemiologic evidence indicated exposures occurred at or near the mill, and genomic findings suggested a common exposure source. Patients with diabetes may have increased risk for hospitalization, and elevated urine antigen titers could indicate greater disease severity. Early suspicion of blastomycosis may prompt earlier diagnosis and treatment, potentially reducing unnecessary antibiotic prescriptions and improving patient outcomes. This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/epidemiological-and-clinical-features-of-a-large-blastomycosis-outbreak-at-a-paper-mill-in-michigan


  • Open Access

    Investigation and successful control of a Candida auris outbreak at a tertiary health care facility in Kenya

    by Loice Achieng Ombajo, Alice Kanyua, Rose Ngugi, Correia Malcolm, Elizabeth Berkow, Lalitha Gade, Elizabeth Bancroft, Joan Osoro, Rachel Njoroge, Phoebe Juma, et al.